Avidity Biosciences to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Avidity Biosciences, Inc. (RNA) announces participation in upcoming healthcare conferences to discuss RNA therapeutics. The company will be present at TD Cowen 44th Annual Health Care Conference, Leerink Partners 2024 Global Biopharma Conference, and Barclays 26th Annual Global Healthcare Conference.

SAN DIEGO, Feb. 27, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating at the following upcoming conferences:

• TD Cowen 44^th Annual Health Care Conference on March 5 at 10:30 a.m. PT/1:30 p.m. ET
• Leerink Partners 2024 Global Biopharma Conference on March 12 at 12:00 p.m. PT/3:00 p.m. ET
• Barclays 26^th Annual Global Healthcare Conference on March 13 at 10:05 a.m. PT/1:05 p.m. ET

A live webcast of each of the events, up-to-date event details and archived replays will be available on the "Events and Presentations" page in the "Investors" section of Avidity's website at https://aviditybiosciences.investorroom.com/events-and-presentations.

About Avidity
Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through internal discovery efforts and key partnerships. Avidity is headquartered in San Diego, CA. For more information about our AOC platform, clinical development pipeline and people, please visit www.aviditybiosciences.com and engage with us on LinkedIn and X.

Investor Contact:
Geoffrey Grande, CFA
(619) 837-5014
investors@aviditybio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-to-participate-in-upcoming-investor-conferences-302071874.html

SOURCE Avidity Biosciences, Inc.

FAQ

When will Avidity Biosciences participate in the TD Cowen 44th Annual Health Care Conference?

Avidity Biosciences will participate in the TD Cowen 44th Annual Health Care Conference on March 5 at 10:30 a.m. PT/1:30 p.m. ET.

What is the focus of Avidity Biosciences' RNA therapeutics?

Avidity Biosciences focuses on delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™).

Where can investors find more information about the upcoming conferences?

Investors can find up-to-date event details and archived replays on the 'Events and Presentations' page in the 'Investors' section of Avidity's website at https://aviditybiosciences.investorroom.com/events-and-presentations.